DPBR112, the first targeted therapy drug for lung cancer to be researched in Taiwan, has an estimated market value of NT$5 billion (US$171.7 million) per year, and could be approved for market launch within five years, the Ministry of Science and Technology said on Tuesday.
Sixty percent of patients with non-small cell lung cancer, who comprise 85 percent of lung cancer patients nationwide, require treatment via targeted therapy, said researcher Hsu Tzu-an (徐祖安) of the National Health Research Institutes’ (NHRI) Institute of Biotechnology and Pharmaceutical Research.
First-generation targeted therapy medication, such as Iressa and Tarceva, have been deemed ineffective, as patients’ easily develop a tolerance to them, Hsu said, adding that second-generation drugs, such as Afatinib, produce side effects.
Lung carcinoma patients in Taiwan, Japan, South Korea and China have a 50 to 60 percent higher chance of developing epidermal growth factor receptor (EFGR) gene mutations, Hsu said.
Four percent of EGFR gene mutations are identified as EGFR exon 20-mutated lung cancer, while another 4 percent develop human epidermal growth factor receptor 2 (HER2) mutations, Hsu said.
Available targeted therapy options abroad are unable to treat both mutation types, Hsu said.
The research team tested the drug against multiple mutated proteins and found that DBPR112 performs well in suppressing effects of wild-type EGFR and its mutated variants, Hsu said, adding that the team also found that DBPR112 has a higher oral absorption rate.
In the tests on mice, the team observed that test subjects seemed to have higher dosage tolerance with lowered toxicity and side effects, Hsu said, adding that the drug’s suppression rates of specific EGFR or HER2-mutated lung carcinoma cells were excellent.
Once DBPR112 launches, patients around the globe would be able to benefit from better targeted therapy medication, Hsu said.
The NHRI began researching the drug after receiving a NT$300 million grant from the ministry, and the seven-year research project completed its preclinical trials last year and is now conducting first-phase human clinical trials, Deputy Minister of Science and Technology Su Fong-chin (蘇芳慶) said.
Patents for the drug have been applied for and approved in Taiwan, the US, China, Japan and South Korea, Su said.
Su called on the biotech industry to support the trials and assist the government’s push for domestically produced pharmaceuticals.
Former Czech Republic-based Taiwanese researcher Cheng Yu-chin (鄭宇欽) has been sentenced to seven years in prison on espionage-related charges, China’s Ministry of State Security announced yesterday. China said Cheng was a spy for Taiwan who “masqueraded as a professor” and that he was previously an assistant to former Cabinet secretary-general Cho Jung-tai (卓榮泰). President-elect William Lai (賴清德) on Wednesday last week announced Cho would be his premier when Lai is inaugurated next month. Today is China’s “National Security Education Day.” The Chinese ministry yesterday released a video online showing arrests over the past 10 years of people alleged to be
THE HAWAII FACTOR: While a 1965 opinion said an attack on Hawaii would not trigger Article 5, the text of the treaty suggests the state is covered, the report says NATO could be drawn into a conflict in the Taiwan Strait if Chinese forces attacked the US mainland or Hawaii, a NATO Defense College report published on Monday says. The report, written by James Lee, an assistant research fellow at Academia Sinica’s Institute of European and American Studies, states that under certain conditions a Taiwan contingency could trigger Article 5 of NATO, under which an attack against any member of the alliance is considered an attack against all members, necessitating a response. Article 6 of the North Atlantic Treaty specifies that an armed attack in the territory of any member in Europe,
LIKE FAMILY: People now treat dogs and cats as family members. They receive the same medical treatments and tests as humans do, a veterinary association official said The number of pet dogs and cats in Taiwan has officially outnumbered the number of human newborns last year, data from the Ministry of Agriculture’s pet registration information system showed. As of last year, Taiwan had 94,544 registered pet dogs and 137,652 pet cats, the data showed. By contrast, 135,571 babies were born last year. Demand for medical care for pet animals has also risen. As of Feb. 29, there were 5,773 veterinarians in Taiwan, 3,993 of whom were for pet animals, statistics from the Animal and Plant Health Inspection Agency showed. In 2022, the nation had 3,077 pediatricians. As of last
XINJIANG: Officials are conducting a report into amending an existing law or to enact a special law to prohibit goods using forced labor Taiwan is mulling an amendment prohibiting the importation of goods using forced labor, similar to the Uyghur Forced Labor Prevention Act (UFLPA) passed by the US Congress in 2021 that imposed limits on goods produced using forced labor in China’s Xinjiang region. A government official who wished to remain anonymous said yesterday that as the US customs law explicitly prohibits the importation of goods made using forced labor, in 2021 it passed the specialized UFLPA to limit the importation of cotton and other goods from China’s Xinjiang Uyghur region. Taiwan does not have the legal basis to prohibit the importation of goods